{"id":38833,"date":"2020-08-28T07:19:46","date_gmt":"2020-08-28T07:19:46","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=38833"},"modified":"2020-08-28T09:21:23","modified_gmt":"2020-08-28T09:21:23","slug":"famotidine-associated-with-better-outcomes-from-covid-19","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/38833","title":{"rendered":"Famotidine associated with better outcomes from COVID-19"},"content":{"rendered":"
\n

<\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

Two studies have reported positive outcomes from COVID-19 in adults using the histamine-2 receptor antagonist famotidine.<\/span><\/strong><\/p>\n<\/div>\n

\n

The larger study included 1620 adults hospitalised with COVID-19 between 25 February and 13 April 2020 of whom 84 (5.1%) received famotidine. Home use of famotidine on admission was documented in 15% of those given famotidine group vs in 1% of those who were not (p=0.01). [1]<\/span><\/p>\n<\/div>\n

\n

Overall, 28% of the famotidine group were dosed intravenously: <\/span>17% were 10 mg, 47% were 20 mg and 35% were 40 mg. Total median dose of 136 mg (63 to 233 mg) was given over a median of 5 days.<\/span><\/p>\n<\/div>\n

\n

A total of 340 participants (21%) met the primary composite endpoint of death or intubation:\u00a0142 (8.8%) patients were intubated and 238 (15%) died.<\/span><\/p>\n<\/div>\n

\n

In adjusted analyses, famotidine was independently associated with risk for death or intubation (adj. HR 0.42, 95% CI: 0.21 to 0.85) which remained after propensity score matching to further balance the covariables (HR: 0.43, 95%CI: 0.21 to 0.88).<\/span><\/p>\n<\/div>\n

\n

This study also found no benefit of proton pump inhibitors or impact of famotidine in people hospitalised who did not have COVID-19.<\/span><\/p>\n<\/div>\n

\n

A second more recent study also reported reduced mortality and intubation associated with famotidine. [2]<\/span><\/p>\n<\/div>\n

\n

This was a retrospective analysis of 878 adults hospitalised with COVID-19 of whom 83 (9.5%) used famotidine. The control group were slightly younger (mean 63 vs 67 years, p=0.02) but propensity-matched for baseline demographics and comorbidities.<\/span><\/p>\n<\/div>\n

\n

Famotidine was associated with decreased risk of in-hospital mortality (OR 0.37, 95%CI: 0.16 to 0.86, p=0.021) and combined death\/intubation (OR 0.47, 95%CI: 0.23 to 0.96, p=0.040).<\/span><\/p>\n<\/div>\n

\n

comment<\/span><\/h3>\n<\/div>\n
\n

Although these associations are important enough to report and famotidine is safe and widely used, results from two phase 3 randomised studies are needed to demonstrate efficacy. [3. 4]<\/span><\/strong><\/p>\n<\/div>\n

\n

Reference<\/span><\/p>\n<\/div>\n

\n
    \n
  1. DE et al. Famotidine use Is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology, DOI: <\/span>10.1053\/j.gastro.2020.05.053. (22 May 2020).
    \nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S0016508520347065<\/a><\/li>\n
  2. Mather JF et al. Impact of famotidine use on clinical outcomes of hospitalised COVID-19 patients. American Journal of Gastroenterology. (14 August 2020).
    \n    https:\/\/journals.lww.com\/ajg\/Documents\/AJG-20-2074_R1.pdf<\/a> (PDF)<\/li>\n
  3. Role of famotidine in the symptomatic improvement of COVID-19 patients.
    \n    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04504240<\/a><\/li>\n
  4. Multi-site adaptive trials for COVID-19.
    \n    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04370262<\/a><\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Two studies have reported positive outcomes from COVID-19 in adults using the histamine-2 receptor antagonist famotidine. The larger study included 1620 adults hospitalised with COVID-19 between 25 February and 13 April 2020 of whom 84 (5.1%) …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-38833","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=38833"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38833\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=38833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=38833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=38833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}